BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hodavance MS, Vikingstad EM, Griffin AS, Pabon-ramos WM, Berg CL, Suhocki PV, Kim CY. Effectiveness of Transarterial Embolization of Hepatocellular Carcinoma as a Bridge to Transplantation. Journal of Vascular and Interventional Radiology 2016;27:39-45. [DOI: 10.1016/j.jvir.2015.08.032] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Jung WJ, Jang S, Choi WJ, Park J, Choi GH, Jang ES, Jeong SH, Choi WS, Lee JH, Yoon CJ, Kim JW. Metformin administration is associated with enhanced response to transarterial chemoembolization for hepatocellular carcinoma in type 2 diabetes patients. Sci Rep 2022;12:14482. [PMID: 36008432 DOI: 10.1038/s41598-022-18341-2] [Reference Citation Analysis]
2 Makary MS, Khandpur U, Cloyd JM, Mumtaz K, Dowell JD. Locoregional Therapy Approaches for Hepatocellular Carcinoma: Recent Advances and Management Strategies. Cancers (Basel) 2020;12:E1914. [PMID: 32679897 DOI: 10.3390/cancers12071914] [Cited by in Crossref: 12] [Cited by in F6Publishing: 35] [Article Influence: 6.0] [Reference Citation Analysis]
3 Bajwa R, Madoff DC, Kishore SA. Embolotherapy for Hepatic Oncology: Current Perspectives and Future Directions. Dig Dis Interv 2020;4:134-47. [PMID: 32832829 DOI: 10.1055/s-0040-1712146] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
4 Kishore SA, Bajwa R, Madoff DC. Embolotherapeutic Strategies for Hepatocellular Carcinoma: 2020 Update. Cancers (Basel) 2020;12:E791. [PMID: 32224882 DOI: 10.3390/cancers12040791] [Cited by in Crossref: 10] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
5 Schmitz S, Lurje G, Ulmer F, Andert A, Bruners P, Schulze-hagen M, Neumann U, Schoening W. Loco-regional hepatocellular carcinoma treatment services as a bridge to liver transplantation. Hepatobiliary & Pancreatic Diseases International 2019;18:228-36. [DOI: 10.1016/j.hbpd.2019.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Shropshire EL, Chaudhry M, Miller CM, Allen BC, Bozdogan E, Cardona DM, King LY, Janas GL, Do RK, Kim CY, Ronald J, Bashir MR. LI-RADS Treatment Response Algorithm: Performance and Diagnostic Accuracy. Radiology. 2019;292:226-234. [PMID: 31038409 DOI: 10.1148/radiol.2019182135] [Cited by in Crossref: 40] [Cited by in F6Publishing: 48] [Article Influence: 13.3] [Reference Citation Analysis]
7 Toesca DAS, Barry A, Sapisochin G, Beecroft R, Dawson L, Owen D, Mouli S, Lewandowski R, Salem R, Chang DT. Clinical Case Panel: Treatment Alternatives for Inoperable Hepatocellular Carcinoma. Semin Radiat Oncol 2018;28:295-308. [PMID: 30309640 DOI: 10.1016/j.semradonc.2018.08.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
8 Koh S, Maki EJ, Kolbeck KJ, Farsad K. Skin ischemia and ulceration as a complication of inferior phrenic artery embolization for hepatocellular carcinoma. Radiology Case Reports 2018;13:648-51. [DOI: 10.1016/j.radcr.2018.02.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Wang Q, Hodavance M, Ronald J, Suhocki PV, Kim CY. Minimal Risk of Biliary Tract Complications, Including Hepatic Abscess, After Transarterial Embolization for Hepatocellular Carcinoma Using Concentrated Antibiotics Mixed with Particles. Cardiovasc Intervent Radiol 2018;41:1391-8. [DOI: 10.1007/s00270-018-1989-x] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
10 Kulik L, Heimbach JK, Zaiem F, Almasri J, Prokop LJ, Wang Z, Murad MH, Mohammed K. Therapies for patients with hepatocellular carcinoma awaiting liver transplantation: A systematic review and meta-analysis. Hepatology 2018;67:381-400. [PMID: 28859222 DOI: 10.1002/hep.29485] [Cited by in Crossref: 127] [Cited by in F6Publishing: 122] [Article Influence: 31.8] [Reference Citation Analysis]
11 Mouli SK, Goff LW. Local Arterial Therapies in the Management of Unresectable Hepatocellular Carcinoma. Curr Treat Options in Oncol 2017;18. [DOI: 10.1007/s11864-017-0509-6] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
12 Tholey DM, Hornung B, Enestvedt CK, Chen Y, Naugler WS, Farsad K, Nabavizadeh N, Schlansky B, Ahn J, Jou JH. Close observation versus upfront treatment in hepatocellular carcinoma: are the exception points worth the risk? BMJ Open Gastroenterol 2017;4:e000157. [PMID: 28944072 DOI: 10.1136/bmjgast-2017-000157] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
13 Gaba RC, Lokken RP, Hickey RM, Lipnik AJ, Lewandowski RJ, Salem R, Brown DB, Walker TG, Silberzweig JE, Baerlocher MO, Echenique AM, Midia M, Mitchell JW, Padia SA, Ganguli S, Ward TJ, Weinstein JL, Nikolic B, Dariushnia SR; Society of Interventional Radiology Standards of Practice Committee. Quality Improvement Guidelines for Transarterial Chemoembolization and Embolization of Hepatic Malignancy. J Vasc Interv Radiol 2017;28:1210-1223.e3. [PMID: 28669744 DOI: 10.1016/j.jvir.2017.04.025] [Cited by in Crossref: 55] [Cited by in F6Publishing: 54] [Article Influence: 11.0] [Reference Citation Analysis]
14 Kishore S, Friedman T, Madoff DC. Update on Embolization Therapies for Hepatocellular Carcinoma. Curr Oncol Rep 2017;19:40. [PMID: 28421483 DOI: 10.1007/s11912-017-0597-2] [Cited by in Crossref: 18] [Cited by in F6Publishing: 20] [Article Influence: 3.6] [Reference Citation Analysis]